As time goes by

The treatment of hypertension using drugs and the achieved benefits of such treatment is founded on a solid body of evidence representing a very large number of well-conducted randomised clinical trials.

Read More
CPD POINTS: 0

Dapagliflozin DECLARE: Latest SGLT2 CV outcomes trial

MEDICAL CHRONICLE DECEMBER 2018 CPD 3 of 3: Recently the DECLARE trial was published evaluating in a randomised, double-blind, multinational, placebo- controlled trial, the effect of Dapagliflozin on safety and efficacy for macrovascular and microvascular outcomes.

Read More
CPD POINTS: 0

Marijuana and the heart: what do we know?

We know little about cannabis consumption and the health effects of it, and more so its effects on cardiovascular disease.

Read More
CPD POINTS: 0

The dos and don’ts of monitoring warfarin

MEDICAL CHRONICLE SEPTEMBER CPD 5 of 5: Since warfarin was given to American president Dwight Eisenhower following a myocardial infarction in 1955, it has been widely used as an oral anticoagulant.

Read More
CPD POINTS: 0

Odyssey Outcome trial: cure for atherosclerosis?

The Odyssey Outcomes trial looked at reduction of LDL-cholesterol with a PCSK9-inhibitor.

Read More
CPD POINTS: 0

BP control with current therapy

Initial combination treatment strategy may improve long-term BP control in a shorter time.

Read More
CPD POINTS: 0

Enter Entresto: A new era in the treatment of heart failure

Globally the prevalence of heart failure is about one in 25 of the general population with increasing prevalence with increasing age.

Read More
CPD POINTS: 3

New product launch: Dynaval

Pharma Dynamics announces the addition of Dynaval (valsartan) to its range of cardiovascular medicines.

Read More
CPD POINTS: 0

Women’s hearts

Premature deaths caused by heart and blood vessel diseases (CVD) in people of working age (35-64 years) are expected to increase by 41% between 2000 and 2030.

Read More
CPD POINTS: 0

Risk of sudden death in heart failure

Current recommended treatment for heart failure: Angiotensin-converting enzyme inhibitor (ACE-Inhibitors) or Angiotensin-receptor blockers (ARB), beta-blockers (Carvedilol, Bisoprolol and Metoprolol) and mineralocorticoid receptor antagonists.

Read More
CPD POINTS: 0

Issues in hypertension

Hypertension increases the risk for coronary heart disease by two-fold and the risk for heart failure and stroke by four-fold.

Read More
CPD POINTS: 0

What is the impact on CVD outcome of non-adherence?

As measured over the last two decades, the mortality from cardiovascular disease (CVD) has declined by about 50% and at least half of this decline has been   attributed to the use of evidence-based medication.  

Read More
CPD POINTS: 0

Heart failure with preserved ejection fraction

Heart failure with reduced ejection fraction has shown improved outcomes with evidence-based treatment but heart failure with preserved ejection fraction has not shown any improved outcomes with treatment demonstrating our lack of effective therapies for this condition.

Read More
CPD POINTS: 0

Stable angina pectoris

Ischaemic heart disease refers to a state in which there is inadequate blood supply (oxygen) to a portion of the myocardium due to an imbalance of myocardial oxygen supply and myocardial oxygen demand.

Read More
CPD POINTS: 0

Manifestations of the metabolic syndrome: Part 1

This article deals with the definition, investigations, epidemiology and aetiology of metabolic syndrome.

Read More
CPD POINTS: 0

Manifestations of the metabolic syndrome: part 2

Continuing on from Manifestations of the Metabolic Syndrome: Part 1, which appeared in the February issue of Medical Chronicle, which was all about diagnostic numbers, we look further at pathophysiology, progression, clinical presentations, prevention and practical management of the metabolic syndrome (Met-S).

Read More
CPD POINTS: 0